JonesResearch initiated coverage of Palvella Therapeutics (PVLA) with a Buy rating and $45 price target The company’s Qtorin platform delivers drugs to the skin for rare derm indications, starting with a topical re-formulation of sirolimus for cutaneous mTOR-driven disorders, the analyst tells investors in a research note. The firm likes like Palvella’s approach to micro microcystic lymphatic malformations.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds